The extra fat we carry around our middle could be making us hungrier, so we eat more, which in turn leads to even more belly fat. Dr. Yaiping Yang and his colleagues at the Lawson Health Research Institute affiliated with The University of Western Ontario found abdominal fat tissue can reproduce a hormone that stimulates fat cell production. The researchers hope this discovery will change in the way we think about and treat abdominal obesity.
Yang identified that the hormone Neuropeptide Y (NPY) is reproduced by abdominal fat tissue. Previously, it was believed to only be produced by the brain. Yang believes this novel finding may lead to new therapeutic targets for combating obesity. Their findings were reported in a recent issue of The FASEB Journal.
The traditional view is that one of the main reasons why overweight people eat more food is because their brains produce the hormone NPY in excessive amounts. NPY is the most potent appetite stimulating hormone known, sending signals to the individual that they are constantly hungry. However, Yang, a Professor in the Departments of Obstetrics & Gynaecology and Physiology & Pharmacology at the Schulich School of Medicine & Dentistry at The University of Western Ontario, has provided evidence that in obese rat models NPY is also produced locally by abdominal fat.
A fat cell cannot replicate itself. But the researchers found NPY increases fat cell number by stimulating the replication of fat cell precursor cells, which then change into fat cells.
Yang says “this may lead to a vicious cycle where NPY produced in the brain causes you to eat more and therefore gain more fat around your middle, and then that fat produces more NYP hormone which leads to even more fat cells.”
Being overweight, regardless of where the fat is located, is unhealthy. However, because of its anatomical location and its byproducts, abdominal fat or the apple-shape is known to be the most dangerous. People predisposed to the apple shape are at an elevated risk for heart disease, Type 2 diabetes, hypertension and some cancers.
Next, the researchers will be investigating whether NPY produced by fat is released into the body’s circulatory system. “We want to know if NPY could potentially be transported in the blood to the brain where it in turn has an impact on the brain to stimulate feelings of hunger,” says Yang. If the researchers find that NPY is in fact transported in the blood circulation then it may be possible to develop a simple blood test to detect increased levels of NPY. “If you can detect NPY early and identify those at risk for abdominal obesity we can then target therapy to turn off NPY. It would be much easier to use drugs to prevent obesity than to treat the diseases caused by obesity.”
Source: University of Western Ontario
Related stories:
How we can stop stress from making us obese
In what they call a “stunning research advance,” investigators at Georgetown University Medical Center have been able to use simple, non-toxic chemical injections to add and remove fat in targeted areas on the bodies of laboratory animals. They say the discovery, published online in
Nature Medicine on July 1, could revolutionize human cosmetic and reconstructive plastic surgery and treatment of diseases associated with human obesity.
New catheter-less technique may ease the pain and discomfort of prostate cancer recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.
Bisphenol A linked to metabolic syndrome in human tissue
New research from the University of Cincinnati (UC) implicates the primary chemical used to produce hard plastics—bisphenol A (BPA)—as a risk factor for metabolic syndrome and its consequences.
Obesity raises risks of serious digestive health concerns
The prevalence of obesity and overweight in the United States coupled by the increased risk of gastrointestinal diseases related to obesity raises serious implications for the health of Americans. Several scientific studies in the August issue of
The American Journal of Gastroenterology examine the association between obesity and the risk of colorectal cancer and gastroesophageal reflux disease, or GERD.
Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy
Low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in a group of patients with HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection. However, growth hormone treatment appeared to increase blood glucose levels, particularly in those already exhibiting glucose intolerance. The study from researchers at Massachusetts General Hospital (MGH) appears in the Aug.. 6
Journal of the American Medical Association, a special issue on HIV/AIDS.
Weight Watchers vs. fitness centers
In the first study of its kind, using sophisticated methods to measure body composition, the nationally known commercial weight loss program, Weight Watchers, was compared to gym membership programs to find out which method wins in the game of good health. A University of Missouri researcher examined the real-life experiences of participants to determine which program helps people lose pounds, reduce body fat and gain health benefits. The answer is that both have pros and cons and that a combination of the two produces the best results.
Lifestyle can alter gene activity, lead to insulin resistance
A Finnish study of identical twins has found that physical inactivity and acquired obesity can impair expression of the genes which help the cells produce energy. The findings suggest that lifestyle, more than heredity, contributes to insulin resistance in people who are obese. Insulin resistance increases the chance of developing diabetes and heart disease.
Diabetes drug slows early-onset puberty in girls
In young girls at risk of early puberty and insulin resistance, the diabetes drug metformin delayed the onset of menstruation and decreased the development of insulin resistance, a risk factor for type 2 diabetes, according to a new study. The results were presented Monday, June 16, at The Endocrine Society's 90th Annual Meeting in San Francisco.